CytomX Therapeutics, Inc. (NASDAQ:CTMX) CEO Sean A. Mccarthy Sells 37,656 Shares

CytomX Therapeutics, Inc. (NASDAQ:CTMX) CEO Sean A. Mccarthy sold 37,656 shares of the stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $0.60, for a total value of $22,593.60. Following the sale, the chief executive officer now directly owns 995,195 shares in the company, valued at approximately $597,117. The trade was a 3.65 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

CytomX Therapeutics Price Performance

NASDAQ:CTMX traded down $0.00 during mid-day trading on Thursday, reaching $0.67. The company’s stock had a trading volume of 696,292 shares, compared to its average volume of 2,626,571. The company’s fifty day simple moving average is $0.77 and its two-hundred day simple moving average is $0.99. CytomX Therapeutics, Inc. has a twelve month low of $0.56 and a twelve month high of $5.85. The stock has a market cap of $53.34 million, a P/E ratio of 3.92 and a beta of 1.05.

CytomX Therapeutics (NASDAQ:CTMX) last released its quarterly earnings data on Thursday, March 6th. The biotechnology company reported $0.22 earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.45. The business had revenue of $38.09 million for the quarter, compared to analyst estimates of $13.53 million. CytomX Therapeutics had a negative return on equity of 41.47% and a net margin of 10.96%. Sell-side analysts expect that CytomX Therapeutics, Inc. will post -0.05 EPS for the current fiscal year.

Institutional Investors Weigh In On CytomX Therapeutics

Several hedge funds have recently modified their holdings of the stock. Prosight Management LP raised its holdings in shares of CytomX Therapeutics by 29.2% during the 4th quarter. Prosight Management LP now owns 3,905,000 shares of the biotechnology company’s stock valued at $4,022,000 after buying an additional 882,891 shares during the period. Millennium Management LLC increased its holdings in CytomX Therapeutics by 25.8% during the 4th quarter. Millennium Management LLC now owns 3,221,012 shares of the biotechnology company’s stock worth $3,318,000 after purchasing an additional 660,756 shares during the last quarter. Point72 Asset Management L.P. purchased a new stake in CytomX Therapeutics during the 4th quarter worth approximately $2,730,000. Jacobs Levy Equity Management Inc. increased its holdings in CytomX Therapeutics by 1.5% during the 4th quarter. Jacobs Levy Equity Management Inc. now owns 1,547,215 shares of the biotechnology company’s stock worth $1,594,000 after purchasing an additional 23,139 shares during the last quarter. Finally, Schonfeld Strategic Advisors LLC increased its holdings in CytomX Therapeutics by 13.9% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 1,380,800 shares of the biotechnology company’s stock worth $1,422,000 after purchasing an additional 169,000 shares during the last quarter. 67.77% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms recently commented on CTMX. HC Wainwright reaffirmed a “neutral” rating on shares of CytomX Therapeutics in a research note on Friday, March 7th. Wedbush reaffirmed an “outperform” rating and set a $5.00 price objective on shares of CytomX Therapeutics in a research note on Friday, March 7th. Finally, StockNews.com raised CytomX Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, March 10th. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, CytomX Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $5.02.

About CytomX Therapeutics

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.